Targets › GPC2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2027.
Cell surface proteoglycan that bears heparan sulfate. May fulfill a function related to the motile behaviors of developing neurons (By similarity). (UniProt, Q8N158)
Open in Phaseline: the race on GPC2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stanford University | GPC2-CAR T cells Anti-GPC2 chimeric antigen receptor T cells | GPC2 | Phase 1 | Medulloblastoma | Aug 2027 |
Medulloblastoma (1)
mixed (1)
Stanford University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.